Breast Cancer Trial, Recruiting NCT05416164 Sponsor: The Netherlands Cancer Institute Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT05416164
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older
  • People diagnosed with invasive breast cancer that is hormone receptor positive/HER2 negative, HER2 positive (with or without hormone receptors), or triple negative
  • People whose biopsy before treatment also showed a non-invasive breast cell change (called DCIS), as long as there is no sign that it is widespread based on imaging scans and mammogram results
  • People whose tumour was classified as an early stage (stage 1 or 2) based on size at the time of diagnosis
  • People with a single tumour in one breast, confirmed by specialised imaging scans before treatment
  • People with no cancer detected in the lymph nodes before treatment, confirmed by ultrasound or a specific type of full-body scan (FDG-PET/CT)
  • People who received chemotherapy or other systemic (whole-body) treatment before surgery, known as neoadjuvant systemic treatment
  • People who had a small marker or clip placed into the breast tumour before starting pre-surgery treatment
  • People who had breast-conserving surgery (removal of the tumour only, not the whole breast)
  • People who had a sentinel node biopsy (a procedure to check nearby lymph nodes) either before or after pre-surgery treatment
  • People whose post-surgery pathology results showed a complete response, meaning no cancer cells or DCIS were found in the breast or lymph nodes after treatment
  • People who have provided written consent to participate in the trial

Who may not be able to join:

  • People whose tumour was classified as a more advanced stage (stage 3 or 4) based on size at diagnosis
  • People found to have cancer in their lymph nodes at any point before or after pre-surgery treatment, including very small amounts of cancer cells
  • People who did not have an axillary (underarm) ultrasound or FDG-PET/CT scan before starting pre-surgery treatment
  • People with a previous history of breast cancer or non-invasive breast cell changes (DCIS)
  • People with a simultaneous breast cancer or DCIS in the opposite breast
  • People with cancer that had already spread to other parts of the body at the time of diagnosis
  • People who carry certain gene mutations known to increase the risk of breast cancer, including BRCA1, BRCA2, CHEK2, TP53, or PALB-2

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +31(0)20 5126170

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The Netherlands Cancer Institute
Registry
ClinicalTrials.gov
Start date
7 October 2022
Est. completion
1 May 2032

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Local recurrence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov